{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T07:13:41Z","timestamp":1785827621707,"version":"3.56.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004901","name":"Minas Gerais State Foundation of Support to the Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordination of Higher Education Personnel Improvement","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.vaccine.2021.04.004","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T18:00:59Z","timestamp":1618682459000},"page":"2755-2763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB\/c mice"],"prefix":"10.1016","volume":"39","author":[{"given":"Thais Lopes Valentim Di Paschoale","family":"Ostolin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miri\u00e3 Rodrigues","family":"Gusm\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Augusto Siqueira","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamille Mirelle de Oliveira","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Mendes","family":"Roatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Dian de Oliveira","family":"Aguiar-Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeronimo Concei\u00e7\u00e3o","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela de Melo","family":"Resende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory Cristiane Fortes","family":"de Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Barbosa","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.04.004_b0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003374","article-title":"Prognostic factors and scoring system for death from visceral leishmaniasis: an historical cohort study in Brazil","volume":"8","author":"Coura-Vital","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2021.04.004_b0010","unstructured":"WHO | Integrating neglected tropical diseases in global health and development. WHO; 2019."},{"key":"10.1016\/j.vaccine.2021.04.004_b0015","unstructured":"Leishmaniasis - PAHO\/WHO | Pan American Health Organization; n.d. https:\/\/www.paho.org\/en\/topics\/leishmaniasis (accessed March 6, 2021)."},{"key":"10.1016\/j.vaccine.2021.04.004_b0020","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1590\/S0037-86822011005000014","article-title":"Quanto \u00e9 efetivo o abate de c\u00e3es para o controle do calazar zoon\u00f3tico? Uma avalia\u00e7\u00e3o cr\u00edtica da ci\u00eancia, pol\u00edtica e \u00e9tica por tr\u00e1s desta pol\u00edtica de sa\u00fade p\u00fablica","volume":"44","author":"Costa","year":"2011","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.vaccine.2021.04.004_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2019.00168","article-title":"Assessment of vaccine-induced immunity against canine visceral leishmaniasis","volume":"6","author":"Moreno","year":"2019","journal-title":"Front Vet Sci"},{"key":"10.1016\/j.vaccine.2021.04.004_b0030","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.drudis.2008.12.007","article-title":"The use of genomics in microbial vaccine development","volume":"14","author":"Bambini","year":"2009","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.vaccine.2021.04.004_b0035","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1590\/0037-8682-0120-2016","article-title":"Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis","volume":"49","author":"Duarte","year":"2016","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.vaccine.2021.04.004_b0040","doi-asserted-by":"crossref","DOI":"10.1186\/s13071-016-1553-y","article-title":"Possibilities and challenges for developing a successful vaccine for leishmaniasis","volume":"9","author":"Srivastava","year":"2016","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.vaccine.2021.04.004_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00813","article-title":"Nucleoside hydrolase NH 36: A vital enzyme for the Leishmania genus in the development of T-cell epitope cross-protective vaccines","volume":"10","author":"Palatnik-De-Sousa","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0050","article-title":"Vaccine informatics","volume":"2010","author":"He","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0055","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/S0264-410X(00)00554-5","article-title":"Reverse vaccinology, a genome-based approach to vaccine development","volume":"19","author":"Rappuoli","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.004_b0060","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ymeth.2004.06.004","article-title":"From genome to vaccine - New immunoinformatics tools for vaccine design","volume":"34","author":"De Groot","year":"2004","journal-title":"Methods"},{"key":"10.1016\/j.vaccine.2021.04.004_b0065","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1586\/14760584.4.3.407","article-title":"Information technologies for vaccine research","volume":"4","author":"Brusic","year":"2005","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.04.004_b0070","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.apjtm.2015.06.008","article-title":"Immunogenicity and efficacy of recombinant 78 kDa antigen of Leishmania donovani formulated in various adjuvants against murine visceral leishmaniasis","volume":"8","author":"Nagill","year":"2015","journal-title":"Asian Pac J Trop Med"},{"key":"10.1016\/j.vaccine.2021.04.004_b0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/08830185.2019.1657426","article-title":"Immunoinformatics: in silico approaches and computational design of a multi-epitope, immunogenic protein","volume":"38","author":"Bahrami","year":"2019","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0080","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12359","article-title":"A recombinant chimeric protein composed of human and mice-specific CD4+ and CD8+ T-cell epitopes protects against visceral leishmaniasis","volume":"39","author":"Martins","year":"2017","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.trsl.2018.05.001","article-title":"Vaccination with a CD4 + and CD8 + T-cell epitopes-based recombinant chimeric protein derived from Leishmania infantum proteins confers protective immunity against visceral leishmaniasis","volume":"200","author":"Dias","year":"2018","journal-title":"Transl Res"},{"key":"10.1016\/j.vaccine.2021.04.004_b0090","article-title":"Chimeric vaccines designed by immunoinformatics-activated polyfunctional and memory T cells that trigger protection against experimental visceral leishmaniasis","author":"De Brito","year":"202080","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2021.04.004_b0095","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0264-410X(96)00293-9","article-title":"Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations","volume":"15","author":"Newman","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.004_b0100","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/S0264-410X(02)00209-8","article-title":"QS-21 structure\/function studies: effect of acylation on adjuvant activity","volume":"20","author":"Liu","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.004_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040745","article-title":"Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: Saponin, incomplete freund\u2019s adjuvant, and monophosphoryl lipid A","volume":"7","author":"Vitoriano-Souza","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2021.04.004_b0110","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007302","article-title":"Randomized controlled trial of RTS, S\/AS02D and RTS, S\/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children","volume":"4","author":"Owusu-Agyei","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.04.004_b0120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"Didierlaurent","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2021.04.004_b0125","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/j.vaccine.2009.01.084","article-title":"Mechanism of action of licensed vaccine adjuvants","volume":"27","author":"Tritto","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.004_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00114","article-title":"Mechanisms of action of adjuvants","volume":"4","author":"Awate","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0135","doi-asserted-by":"crossref","unstructured":"Vitoriano-Souza J, Siqueira Mathias FA, Moreira N das D, Aguiar-Soares RD de O, de Abreu Vieira PM, Teixeira-Carvalho A, et al. Effect on cellular recruitment and the innate immune response by combining saponin, monophosphoryl lipid-A and Incomplete Freund\u2019s Adjuvant with Leishmania (Viannia) braziliensis antigens for a vaccine formulation. Vaccine 2019;37:7269\u201379. https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.067.","DOI":"10.1016\/j.vaccine.2019.09.067"},{"key":"10.1016\/j.vaccine.2021.04.004_b0140","doi-asserted-by":"crossref","unstructured":"Moreira N das D, Vitoriano-Souza J, Roatt BM, Vieira PM de A, Ker HG, de Oliveira Cardoso JM, et al. Parasite Burden in Hamsters Infected with Two Different Strains of Leishmania (Leishmania) infantum: \u201cLeishman Donovan Units\u201d versus Real-Time PCR. PLoS One 2012;7. https:\/\/doi.org\/10.1371\/journal.pone.0047907.","DOI":"10.1371\/journal.pone.0047907"},{"key":"10.1016\/j.vaccine.2021.04.004_b0145","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.vetimm.2006.02.001","article-title":"Isotype patterns of immunoglobulins: Hallmarks for clinical status and tissue parasite density in brazilian dogs naturally infected by Leishmania (Leishmania) chagasi","volume":"112","author":"Reis","year":"2006","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines7040162","article-title":"Synthetic peptides elicit strong cellular immunity in visceral leishmaniasis natural reservoir and contribute to long-lasting polyfunctional T-cells in BALB\/c mice","volume":"7","author":"De Brito","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2021.04.004_b0155","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.vetpar.2013.07.006","article-title":"Molecular diagnosis of canine visceral leishmaniasis: A comparative study of three methods using skin and spleen from dogs with natural Leishmania infantum infection","volume":"197","author":"Reis","year":"2013","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0160","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.vetpar.2015.01.003","article-title":"Canine Leishmania vaccines: still a long way to go","volume":"208","author":"Gradoni","year":"2015","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00241","article-title":"Biomarkers of safety and immune protection for genetically modified live attenuated Leishmania vaccines against visceral leishmaniasis - discovery and implications","volume":"5","author":"Gannavaram","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cyto.2018.07.001","article-title":"The impact of IL-10 dynamic modulation on host immune response against visceral leishmaniasis","volume":"112","author":"Mesquita","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.vaccine.2021.04.004_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007880","article-title":"Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral leishmaniasis in experimental mouse model","volume":"4","author":"Sachdeva","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.04.004_b0180","doi-asserted-by":"crossref","first-page":"7620","DOI":"10.1128\/IAI.73.11.7620-7628.2005","article-title":"Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection","volume":"73","author":"Roberts","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2021.04.004_b0185","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.micinf.2017.03.002","article-title":"Immuno-informatics based approaches to identify CD8+ T cell epitopes within the Leishmania donovani 3-ectonucleotidase in cured visceral leishmaniasis subjects","volume":"19","author":"Vijayamahantesh","year":"2017","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2021.04.004_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01763","article-title":"Identification of potential MHC Class-II-restricted epitopes derived from Leishmania donovani antigens by reverse vaccinology and evaluation of their CD4+ T-cell responsiveness against visceral leishmaniasis","volume":"8","author":"Dikhit","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0195","doi-asserted-by":"crossref","first-page":"5964","DOI":"10.1016\/j.vaccine.2009.07.069","article-title":"The Chimerical Multi-Component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection","volume":"27","author":"Carcel\u00e9n","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.004_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109098","article-title":"Functional aspects of T cell diversity in visceral leishmaniasis","volume":"117","author":"Jawed","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.vaccine.2021.04.004_b0205","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2021.04.004_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00100","article-title":"A chimera containing CD4+ and CD8+ T-cell epitopes of the Leishmania donovani nucleoside hydrolase (NH36) optimizes cross-protection against Leishmania amazonesis infection","volume":"8","author":"Alves-Silva","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0215","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.1016\/j.vaccine.2016.08.051","article-title":"An inflammatory response is essential for the development of adaptive immunity-immunogenicity and immunotoxicity","volume":"34","author":"Nakayama","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.04.004_b0220","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nri933","article-title":"The immunology of susceptibility and resistance to Leishmania major in mice","volume":"2","author":"Sacks","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0225","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1084\/jem.20061886","article-title":"CD4+CD25-Foxp3- Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis","volume":"204","author":"Anderson","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2021.04.004_b0230","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.4049\/jimmunol.166.2.1141","article-title":"The role of IL-10 in promoting disease progression in leishmaniasis","volume":"166","author":"Kane","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0235","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.ijbiomac.2018.08.125","article-title":"Immunoinformatics-aided design of a potential multi-epitope peptide vaccine against Leishmania infantum","volume":"120","author":"Vakili","year":"2018","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0240","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.patbio.2015.03.002","article-title":"Cathelicidin related antimicrobial peptide, laminin, Toll-like receptors and chemokines levels in experimental hypersensitivity pneumonitis in mice","volume":"63","author":"Golec","year":"2015","journal-title":"Pathol Biol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0245","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1074\/jbc.M115.683011","article-title":"Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants","volume":"291","author":"Marty-Roix","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2021.04.004_b0250","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pt.2010.04.005","article-title":"Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis","volume":"26","author":"Reis","year":"2010","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2021.04.004_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/vaccines8020289","article-title":"Liposomal formulation of chimerat, a multiple t-cell epitope-containing recombinant protein, is a candidate vaccine for human visceral leishmaniasis","volume":"8","author":"Lage","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2021.04.004_b0260","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.0105-2896.2004.00188.x","article-title":"The immunopathology of experimental visceral leishmaniasis","volume":"201","author":"Kaye","year":"2004","journal-title":"Immunol Rev"},{"key":"10.1016\/j.vaccine.2021.04.004_b0265","doi-asserted-by":"crossref","DOI":"10.1186\/s13071-016-1413-9","article-title":"Study of Leishmania pathogenesis in mice: experimental considerations","volume":"9","author":"Loeuillet","year":"2016","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.vaccine.2021.04.004_b0270","doi-asserted-by":"crossref","DOI":"10.1186\/1297-9716-42-39","article-title":"Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB\/c mouse versus syrian hamster model","volume":"42","author":"Nieto","year":"2011","journal-title":"Vet Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21004291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21004291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:55:04Z","timestamp":1759402504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21004291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":54,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0264410X21004291"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.004","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB\/c mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}